Financial Daily from THE HINDU group of publications
Wednesday, Apr 26, 2006
Financial Daily from THE HINDU group of publications Wednesday, Apr 26, 2006 |
|
|
|
|
|
|
|
Corporate
-
Corporate Disputes Austrian panel rules in Ranbaxy's favour on lipitor Our Bureau
New Delhi , April 25 In a boost to the country's largest drugmaker Ranbaxy Laboratories Ltd, an Austrian panel has ruled in the company's favour in a patent litigation against Pfizer involving cholesterol-lowering drug `Lipitor' in that country. A five-judge panel of the Supreme Patent and Trademark Board of Austria (OPM) has unanimously affirmed an earlier ruling of the Austrian Patent Office, Ranbaxy said in a statement here. "We are pleased with the decision rendered by the Supreme Patent and Trademark Board of Austria," the RLL Chief Executive Officer and Managing Director, Mr Malvinder M. Singh, said. "Our success further validates our strategy to successfully commercialise Atorvastatin in Austria, and potentially other healthcare markets in the future," he added. In March last year, the Austrian Patent Office had ruled Pfizer's Austrian Patent `AT 207896' (covering Atorvastatin calcium) as invalid for lack of novelty over Pfizer's International Patent Application PCT/US89/00719, published as WO 89/07598 and lack of inventive step over United States Patent No. 4,681,893, the release said.
More Stories on : Corporate Disputes | Pharmaceuticals | IPR | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|